

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

HCC1143

RRID:CVCL_1245

Type: Cell Line

Proper Citation

RRID:CVCL_1245

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1245

Proper Citation: RRID:CVCL_1245

Description: Cell line HCC1143 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:16959974](#), [PMID:17157791](#), [PMID:17932254](#), [PMID:19582160](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21778573](#), [PMID:22414580](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25576301](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AKT genetic alteration cell panel (ATCC TCP-1029)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1143

Synonyms: HCC-1143, Hamon Cancer Center 1144

Cross References: CLO:CLO_0003630, EFO:EFO_0001169, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-2321, BioGRID_ORCS_Cell_line:667, BioSample:SAMN01821553, BioSample:SAMN01821627, BioSample:SAMN03471844, BioSample:SAMN10987917, cancercellines:CVCL_1245, Cell_Model_Passport:SIDM00866, ChEMBL-Cells:ChEMBL3308737, ChEMBL-Targets:ChEMBL1075453, CLS:305545, Cosmic:749710, Cosmic:904360, Cosmic:1047708, Cosmic:1176639, Cosmic:1235079, Cosmic:1287934, Cosmic:1430347, Cosmic:1460230, Cosmic:1473032, Cosmic:1518109, Cosmic:1603198, Cosmic:1935003, Cosmic:2009509, Cosmic:2164989, Cosmic-CLP:749710, dbGAP:phs001839.v1.p1, DepMap:ACH-000374, DSMZ:ACC-517, DSMZCellDive:ACC-517, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:749710, GEO:GSE82032, GEO:GSM184404, GEO:GSM184405, GEO:GSM217570, GEO:GSM274677, GEO:GSM303672, GEO:GSM303674, GEO:GSM303676, GEO:GSM303677, GEO:GSM303678, GEO:GSM303679, GEO:GSM303681, GEO:GSM303683, GEO:GSM303685, GEO:GSM303686, GEO:GSM303688, GEO:GSM303690, GEO:GSM303692, GEO:GSM303693, GEO:GSM303694, GEO:GSM303696, GEO:GSM303697, GEO:GSM303699, GEO:GSM303701, GEO:GSM303702, GEO:GSM303703, GEO:GSM303705, GEO:GSM303706, GEO:GSM303708, GEO:GSM303710, GEO:GSM303711, GEO:GSM303713, GEO:GSM303714, GEO:GSM303716, GEO:GSM303717, GEO:GSM303718, GEO:GSM303720, GEO:GSM303722, GEO:GSM303724, GEO:GSM303725, GEO:GSM303727, GEO:GSM303728, GEO:GSM303730, GEO:GSM303732, GEO:GSM303733, GEO:GSM303734, GEO:GSM303736, GEO:GSM303737, GEO:GSM303739, GEO:GSM303741, GEO:GSM303743, GEO:GSM303744, GEO:GSM303746, GEO:GSM303748, GEO:GSM303749, GEO:GSM303751, GEO:GSM303752, GEO:GSM303755, GEO:GSM303756, GEO:GSM303757, GEO:GSM303758, GEO:GSM303759, GEO:GSM303761, GEO:GSM303763, GEO:GSM303764, GEO:GSM303765, GEO:GSM303767, GEO:GSM303768, GEO:GSM303771, GEO:GSM303772, GEO:GSM303773, GEO:GSM303774, GEO:GSM303776, GEO:GSM303778, GEO:GSM303779, GEO:GSM303781, GEO:GSM303782, GEO:GSM303783, GEO:GSM303785, GEO:GSM303787, GEO:GSM303788, GEO:GSM303790, GEO:GSM337641, GEO:GSM337642, GEO:GSM337643, GEO:GSM337644, GEO:GSM337645, GEO:GSM337646, GEO:GSM337647, GEO:GSM337648, GEO:GSM337649, GEO:GSM337650, GEO:GSM337651, GEO:GSM337652, GEO:GSM337653, GEO:GSM337654, GEO:GSM337655, GEO:GSM337656, GEO:GSM337657, GEO:GSM337658, GEO:GSM337659, GEO:GSM337660, GEO:GSM337661, GEO:GSM344378, GEO:GSM344428, GEO:GSM350550, GEO:GSM481298, GEO:GSM533400, GEO:GSM533407, GEO:GSM537970, GEO:GSM783932, GEO:GSM844541, GEO:GSM847319, GEO:GSM854615, GEO:GSM854616, GEO:GSM854617, GEO:GSM854618, GEO:GSM854619, GEO:GSM887033, GEO:GSM888103, GEO:GSM1008895, GEO:GSM1053704, GEO:GSM1172861, GEO:GSM1172954, GEO:GSM1214576, GEO:GSM1215281, GEO:GSM1215282, GEO:GSM1215283, GEO:GSM1215284, GEO:GSM1215285, GEO:GSM1215286, GEO:GSM1215287, GEO:GSM1215288, GEO:GSM1374493, GEO:GSM1401661, GEO:GSM1669841, IARC_TP53:21359, IARC_TP53:22809, IARC_TP53:30200, IGRhCellID:HCC1143, LiGeA:CCLE_262, LINCS_HMS:50205, LINCS_LDP:LCL-1329, Pharmacodb:HCC1143_466_2019,

PRIDE:PXD000309, PRIDE:PXD000394, PRIDE:PXD002486, PRIDE:PXD005295, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_1245, PubChem_Cell_line:CVCL_1245, SLKBase:3503, Wikidata:Q54881530

ID: CVCL_1245

Record Creation Time: 20220427T220317+0000

Record Last Update: 20260913T003949+0000

Ratings and Alerts

No rating or validation information has been found for HCC1143.

No alerts have been found for HCC1143.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 290 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Cobb DA, et al. (2026) $\gamma\delta$ CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer. Molecular cancer therapeutics, 25(7), 1181.

Matsuura K, et al. (2026) Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. Cell reports, 45(7), 117630.

Burnham CM, et al. (2026) An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates. The Journal of biological chemistry, 302(4), 111302.

Zhang Y, et al. (2025) Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform. Cell reports. Medicine, 6(7), 102198.

Devlin KL, et al. (2025) Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer. Cell reports, 45(1), 116826.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12),

102478.

Regner MJ, et al. (2025) Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling. *Cell genomics*, 5(2), 100765.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. *Frontiers in oncology*, 15, 1549282.

Komar ZM, et al. (2025) Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells. *Cancers*, 17(13).

Williams J, et al. (2025) Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis. *Nature communications*, 16(1), 7438.

Zheng S, et al. (2025) Phosphorylation of plectin by Akt3 promotes triple-negative breast cancer cell invasive migration. *iScience*, 28(10), 113552.

Burnham CM, et al. (2025) An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates. *bioRxiv : the preprint server for biology*.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. *Cell chemical biology*.

Cetin M, et al. (2024) A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer. *Cell chemical biology*.

Cheung A, et al. (2024) Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(15), 3298.

Jové V, et al. (2024) Type I interferon regulation by USP18 is a key vulnerability in cancer. *iScience*, 27(4), 109593.

Gali A, et al. (2024) Protein kinase D drives the secretion of invasion mediators in triple-negative breast cancer cell lines. *iScience*, 27(2), 108958.

van Houtum EJ, et al. (2024) Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling. *Clinical & translational immunology*, 13(9), e1524.

Vinik Y, et al. (2024) Computational pipeline predicting cell death suppressors as targets for cancer therapy. *iScience*, 27(9), 110859.